Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Woeber, K. A.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

LETTER

Hyperthyroidism

right arrow Kenneth A. Woeber

1 March 1995 | Volume 122 Issue 5 | Pages 393-394


TO THE EDITOR:

I enjoyed the article by Klein and associates [1] on the management of hyperthyroidism. However, I was surprised by their statement that anticoagulation with warfarin is not routinely recommended to prevent arterial thromboembolism in patients with hyperthyroidism and atrial fibrillation who do not have organic heart disease (mitral valve disease) or congestive heart failure. This statement is not consistent with data that the reported frequency of arterial thromboembolism exceeds that of congestive heart failure or mitral valve disease in patients with hyperthyroidism [2-4]. Given the devastating effect of arterial thromboembolism and the documented protective effects of anticoagulation, it seems prudent to routinely recommend warfarin treatment unless contraindications to its use exist.


References
space
up arrowTop
dotReferences

1. Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med. 1994; 121:281-8.

2. Presti CF, Hart RG. Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J. 1989; 117:976-7.

3. Summers VK, Surtees SJ. Thyrotoxicosis and heart disease. Acta Med Scand. 1961; 169:661-71.

4. Woeber KA. Thyrotoxicosis and the heart. N Engl J Med. 1992; 327:94-8.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.





box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Woeber, K. A.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online